This white paper discusses partnering solutions tailored for emerging biopharma (EBP) companies. Although EBPs may only have one or two assets, the total pipeline of EBPs is equivalent to roughly two-thirds of the entire global biopharma industry pipeline. In Japan-Asia Pacific (JAPAC) alone, just under 7000 studies were launched by mid- and small-size EBPs between 2016-2020. 

EBPs can significantly increase their probability of success by collaborating with experienced service providers – particularly those who create small, nimble teams dedicated to emerging biopharma's unique needs. In an increasingly complex drug development and healthcare environment, it is vital for companies to demonstrate value, even if their intention is to be acquired or to out-license their asset following proof-of-concept. Transitioning from transactional to fully integrated outsourced partnering options can be extremely beneficial in this regard, since it enables the company to leverage their partner's therapeutic expertise, resourcing capabilities, and organizational infrastructure.